UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

International journal of cancer, 2017-04, Vol.140 (7), p.1670-1679

2017

Volltextzugriff (PDF)

Antibody-drug conjugates: Current status and future perspectives

Pharmacology & therapeutics (Oxford), 2016-11, Vol.167, p.48-59

2016

Volltextzugriff (PDF)

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

Molecular cancer therapeutics, 2015-11, Vol.14 (11), p.2606-2612

2015

Volltextzugriff (PDF)

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody–Drug Conjugates

Bioconjugate chemistry, 2017-07, Vol.28 (7), p.1826-1833

2017

Volltextzugriff (PDF)

A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo

Journal of controlled release, 2017-10, Vol.264, p.211-218

2017

Volltextzugriff (PDF)

Partially shielded enzymes capable of processing large protein substrates

Chemical communications (Cambridge, England), 2020-05, Vol.56 (38), p.517-5173

2020

Volltextzugriff (PDF)

Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

Molecular cancer therapeutics, 2017-05, Vol.16 (5), p.879-892

2017

Volltextzugriff (PDF)

Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody-Drug Conjugates

Methods in molecular biology (Clifton, N.J.), 2019-01, Vol.2012, p.1

2019

Volltextzugriff (PDF)

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Journal for immunotherapy of cancer, 2019-01, Vol.7 (1), p.16-16, Article 16

2019

Volltextzugriff (PDF)

Characterization of the housekeeping sortase from the human pathogen Propionibacterium acnes : first investigation of a class F sortase

Biochemical journal, 2019-02, Vol.476 (4), p.665-682

2019

Volltextzugriff (PDF)

Cost-effective large-scale expression of proteins for NMR studies

Journal of biomolecular NMR, 2018-08, Vol.71 (4), p.247-262

2018

Volltextzugriff (PDF)

NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS1108-TPS1108

2021

Volltextzugriff (PDF)

Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.LB-197-LB-197

2019

Volltextzugriff (PDF)

Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the sub-endothelial extracellular matrix

International journal of cancer, 2016-12, Vol.140 (7), p.1670-1679

2016

Volltextzugriff (PDF)

Antibody format and drug release rate determine the therapeutic activity of non-internalizing antibody-drug conjugates

Molecular cancer therapeutics, 2015-08, Vol.14 (11), p.2606-2612

2015

Volltextzugriff (PDF)

Protease-Cleavable Linkers Modulate the Anticancer Activity of Non-Internalizing Antibody-Drug Conjugates

Bioconjugate chemistry, 2017-07, Vol.28 (7), p.1826-1833

2017

Volltextzugriff (PDF)

1 – 16 von 16

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(15)
Mit Volltextzugriff
(15)

Publikationsform

Artikel
(16)

Sprache

Englisch
(16)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Non‐internalizing antibody–drug conjugates display potent anti‐cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

Antibody-drug conjugates: Current status and future perspectives

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody–Drug Conjugates

A non-internalizing antibody-drug conjugate based on an anthracycline payload displays potent therapeutic activity in vivo

Partially shielded enzymes capable of processing large protein substrates

Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation

Sortase A Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody-Drug Conjugates

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Characterization of the housekeeping sortase from the human pathogen Propionibacterium acnes : first investigation of a class F sortase

Cost-effective large-scale expression of proteins for NMR studies

NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial

Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer

Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the sub-endothelial extracellular matrix

Antibody format and drug release rate determine the therapeutic activity of non-internalizing antibody-drug conjugates

Protease-Cleavable Linkers Modulate the Anticancer Activity of Non-Internalizing Antibody-Drug Conjugates

Suchergebnisse filtern